---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014822"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:49:09.016448+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio signs enrollment deal with Iterative Health, issues $3M stock to affiliate

## Summary
- Entered MSA with Iterative Health to assist with patient enrollment for Phase 2 study of PALI-2108 in ulcerative colitis.
- Issued 1,536,885 shares at $1.952/share (5-day VWAP) for total $3.0 million to an affiliate of Iterative Health.
- Funds support accelerated enrollment; shares sold in private placement exempt from registration.

## SEC filing metadata
- accession: 0001493152-26-014822
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000149315226014822/0001493152-26-014822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000149315226014822/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014822
- JSON: https://secwatch.observer/filing/0001493152-26-014822.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.